KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery
Patent No. 7,585,311 awarded by the United States Patent and Trademark office for knotless surgery tissue fixation to KFx Medical.
San Diego, CA (PRWEB) September 9, 2009 -- KFx Medical Corporation announced today that on September 8, 2009, it was awarded U.S. Patent No. 7,585,311 by the United States Patent and Trademark office. The key patent covers a broad range of methods used to perform surgical knotless tissue fixation, including the double row tissue repair technique used to restore the rotator cuff to its correct anatomic position.
"This broad seminal patent is an important milestone for our company and was the result of a great team effort over many years by KFx and our patent counsel, Knobbe, Martens, Olson, & Bear," indicated Tate Scott, President and CEO. "Double row repairs restore the correct anatomy and have been demonstrated to result in better clinical outcomes with fewer re-tears of the rotator cuff."
Double row techniques have proven difficult for a number of sports medicine and orthopedic surgeons to perform due to the multitude of knots that must be tied through canuulas and under arthroscopic viewing. KFx's products are designed to eliminate knot tying and reduce the overall surgical time and effort needed for this surgical approach.
About KFx Medical Corporation
Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop clinically relevant solutions to rotator cuff repair. Over four million people seek medical advice for shoulder pain every year; torn rotator cuffs alone account for more than 500,000 surgeries annually, requiring many months of rehabilitation. Traditional minimally invasive techniques, although promising (patients typically experience less pain and regain full range of motion more quickly) require surgeons to have advanced arthroscopy skills. In contrast, KFx provides simple systems for surgeons while ensuring a more anatomical repair for the patient, yielding better clinical outcomes. Investors include: Alloy Ventures, Arboretum Ventures, Charter Life Sciences, Montreux Equity Partners and MB Venture Partners.
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1FbXB0LUluc2UtVGhpci1Ib3JyLUNvdXAtWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
